Sarcoidosis

Summary Sarcoidosis is a systemic disease of unknown cause that is characterised by the formation of immune granulomas in various organs, mainly the lungs and the lymphatic system. Studies show that sarcoidosis might be the result of an exaggerated granulomatous reaction after exposure to unidentifi...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2014-03, Vol.383 (9923), p.1155-1167
Main Authors: Valeyre, Dominique, Prof, Prasse, Antje, Prof, Nunes, Hilario, Prof, Uzunhan, Yurdagul, MD, Brillet, Pierre-Yves, Prof, Müller-Quernheim, Joachim, Prof
Format: Article
Language:English
Subjects:
Biological and medical sciences
Blood & organ donations
Cytokines
Diagnosis, Differential
Diagnostic Imaging - methods
Diarrhea
Drug therapy
Epidemiology
Exercise Test
General aspects
Genetic Predisposition to Disease - genetics
Granuloma - physiopathology
Heart attacks
HLA-D Antigens - physiology
Humans
Immune system
Inflammation - physiopathology
Internal Medicine
Long-Term Care
Medical sciences
Mens health
Pregnancy
Prognosis
Quality of life
Sarcoidosis
Sarcoidosis - diagnosis
Sarcoidosis - drug therapy
Sarcoidosis - etiology
Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis
Skin
Skin diseases
Tuberculosis
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Sarcoidosis is a systemic disease of unknown cause that is characterised by the formation of immune granulomas in various organs, mainly the lungs and the lymphatic system. Studies show that sarcoidosis might be the result of an exaggerated granulomatous reaction after exposure to unidentified antigens in individuals who are genetically susceptible. Several new insights have been made, particularly with regards to the diagnosis and care of some important manifestations of sarcoidosis. The indications for endobronchial ultrasound in diagnosis and for PET in the assessment of inflammatory activity are now better specified. Recognition of unexplained persistent disabling symptoms, fatigue, small-fibre neurological impairment, cognitive failure, and changes to health state and quality of life, has improved. Mortality in patients with sarcoidosis is higher than that of the general population, mainly due to pulmonary fibrosis. Predicted advances for the future are finding the cause of sarcoidosis, and the elucidation of relevant biomarkers, reliable endpoints, and new efficient treatments, particularly in patients with refractory sarcoidosis, lung fibrosis, and those with persistent disabling symptoms.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(13)60680-7